CagriSema: Semaglutide + Amylin Combination Drug
Novo Nordisk's answer to tirzepatide combines the proven power of semaglutide with cagrilintide, a long-acting amylin analog, in a single weekly injection for even greater weight loss.
When Eli Lilly's tirzepatide demonstrated superior weight loss compared to semaglutide, Novo Nordisk needed a response. That response is CagriSema — a combination that pairs their proven semaglutide with cagrilintide, targeting a completely different hormonal pathway. Early results suggest this combination could produce weight loss of 22-25% or more, making it one of the most promising obesity drugs in development.
Investigational Drug Notice
CagriSema is not yet FDA-approved and is in Phase 3 clinical trials. Data discussed reflects currently available trial results, which may change as additional data becomes available.
Understanding Amylin: The Missing Piece
To understand why CagriSema represents a meaningful advance, you need to understand amylin — a hormone that has been largely overlooked in the weight loss medication landscape until recently.
What Is Amylin?
Amylin (also called islet amyloid polypeptide, or IAPP) is a hormone produced by the beta cells of the pancreas — the same cells that produce insulin. When you eat, amylin is co-secreted alongside insulin and performs several important functions:
- Slows gastric emptying: Like GLP-1, amylin delays how quickly food leaves your stomach, promoting prolonged satiety
- Suppresses glucagon: Amylin reduces the release of glucagon after meals, helping prevent post-meal blood sugar spikes
- Promotes satiety: Amylin acts on the area postrema and other brain regions to signal fullness, using a different neural pathway than GLP-1
- Reduces food intake: Through its brain effects, amylin reduces meal size and food intake
Why Combine Amylin with GLP-1?
GLP-1 and amylin regulate appetite through different but complementary pathways. GLP-1 primarily acts through the hypothalamus and reward centers, while amylin works through the area postrema and hindbrain. Activating both systems simultaneously produces greater appetite suppression and weight loss than either alone — a concept known as additive or synergistic pharmacology.
Think of it like this: GLP-1 turns down the volume on hunger signals and food cravings in one part of your brain, while amylin turns down the volume in another part. Together, they quiet hunger more effectively than either could alone.
What Is Cagrilintide?
Cagrilintide is Novo Nordisk's long-acting amylin analog — a synthetic version of amylin that has been modified to last much longer in the body. While natural amylin has a half-life of only about 15-20 minutes, cagrilintide persists for approximately one week, enabling once-weekly dosing.
Pramlintide (brand name Symlin) was the first amylin analog approved by the FDA (in 2005, for diabetes), but it required three-times-daily injections and produced modest weight loss. Cagrilintide's long-acting design overcomes these limitations and delivers more potent effects.
Clinical Trial Results
Phase 2 Data
The Phase 2 trial tested CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) against each component individually and placebo in adults with obesity over 32 weeks:
Phase 2 Results (32 weeks)
Note: The semaglutide-alone arm showed lower weight loss than in STEP trials because participants were still in dose escalation at week 32. Longer trials show the full effect.
Phase 3: The REDEFINE Program
The Phase 3 REDEFINE clinical trial program is testing CagriSema across multiple patient populations:
- REDEFINE 1: Adults with obesity or overweight without diabetes (68 weeks)
- REDEFINE 2: Adults with type 2 diabetes and obesity
- REDEFINE 3: Long-term cardiovascular outcomes study
- REDEFINE 4: Head-to-head comparison with tirzepatide
- Additional trials in specific populations including knee osteoarthritis and heart failure
Early Phase 3 results from REDEFINE 1 have shown average weight loss in the range of 22-25% over 68 weeks, positioning CagriSema as a serious competitor to tirzepatide for the most effective injectable weight loss medication.
CagriSema vs Tirzepatide: The Rivalry
The competition between CagriSema and tirzepatide (Zepbound) represents one of the most significant rivalries in pharmaceutical history. Both approaches produce similar weight loss, but through different mechanisms:
| Factor | CagriSema | Tirzepatide |
|---|---|---|
| Manufacturer | Novo Nordisk | Eli Lilly |
| Mechanism | GLP-1 + Amylin | GLP-1 + GIP |
| Avg Weight Loss | ~22-25% | ~20-22% |
| Dosing | Once weekly (single pen) | Once weekly |
| FDA Status | Phase 3 trials | FDA approved |
| Key Advantage | Dual pathway (brain) | Dual receptor (incretin) |
The REDEFINE 4 trial, which directly compares CagriSema against tirzepatide, will provide the clearest picture of how these two approaches stack up against each other. This head-to-head data will be invaluable for clinicians and patients choosing between options.
What CagriSema Means for Patients
For patients currently using or considering GLP-1 medications, CagriSema represents:
- More options: Having multiple highly effective medications allows for personalized treatment selection based on individual response, tolerability, and insurance coverage
- Competitive pressure on pricing: Competition between Novo Nordisk and Eli Lilly may help drive down costs over time
- An upgrade path: Patients currently on semaglutide who want more weight loss could potentially switch to CagriSema without changing their GLP-1 component
- Complementary mechanism: For patients who plateau on GLP-1-only therapy, adding amylin stimulation through CagriSema could restart weight loss
For information about currently available treatments, visit our treatments page or learn how GLP-1 medications work.
Medical Disclaimer
CagriSema is an investigational drug not yet approved by the FDA. Clinical trial results discussed are preliminary and may not reflect final outcomes. Always consult a licensed healthcare provider about weight loss treatment options. Do not attempt to obtain investigational drugs outside of clinical trials.
Effective GLP-1 Treatments Available Now
While CagriSema is in development, proven treatments are available today at affordable prices.
Get Started TodayMore on pipeline and future
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).